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A new mutation (intron 9 +1 G>T) in the SLC12A3 gene is
linked to Gitelman syndrome in Gypsies.
Background. Gitel syndrome is an inherited tubular disorder
characterized by metabolic alkalosis, hypokalemia, and hypo-
magnesemia of renal origin and hypocalciuria. The majority of
patients with Gitelman syndrome carry inactivating mutations
in the SLC12A3 gene encoding the sodium-chloride cotrans-
porter located in the distal convoluted tubule. The purpose of
this study was to investigate the underlying mutation in Gitel-
man syndrome patients of Gypsy race from different geographic
origin.
Methods. Twenty Gypsy patients with clinical and biochem-
ical features of Gitelman syndrome were investigated by mu-
tational analysis. The patients belonged to 12 unrelated Gypsy
families living in four different European countries. The parents
and unaffected siblings of each patient, as well as the DNA of a
population of 200 healthy control patients, were also analyzed.
Results. All patients were homozygous for the same splice
site mutation, guanine to thymine in the first position of intron
9 of SLC12A3 gene. This mutation was not found in the control
population. Parents were heterozygous for the mutation. De-
spite sharing a common mutation, the clinical manifestations of
the syndrome in the patients varied from lack of symptoms in
six children to severe growth retardation in four.
Conclusion. Demonstration of a novel point mutation within
the SLC12A3 gene in our cohort of Gypsy families with
Gitelman syndrome is highly suggestive of a founder effect. This
finding will facilitate the identification of the genetic defect in
further cases of Gitelman syndrome among the Gypsy popula-
tion. Our study represents the largest series ever published of
patients with Gitelman syndrome having the same underlying
mutation, and supports the lack of correlation between geno-
type and clinical phenotype in this disease.
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Gitelman syndrome (OMIM 263800) was first de-
scribed in 1966 [1]. It is an inherited renal tubular disorder
characterized by hypokalemic alkalosis, hypomagne-
semia in the face of inappropriately high urinary mag-
nesium excretion, and hypocalciuria. The clinical disease
results from defective salt reabsorption in the distal con-
voluted tubule (DCT) followed by secondary hyper-
aldosteronism. Transmission of Gitelman syndrome is
autosomal-recessive. The majority of patients harbor in-
activating mutations in the SLC12A3 gene, encoding the
thiazide-sensitive sodium-chloride cotransporter NCCT
[2]. More than 100 different mutations have been de-
scribed, distributed throughout the transporter protein
with accumulation of the mutations in the C-terminus
[3]. A certain mutational hotspot has not been reported
so far.
The Roma (Gypsies) account for a large ethnic minor-
ity within the European population. It is estimated that
8–10 million live in Europe, although particular cultural
and social features of gypsies limit the reliability of census
data. To date, 10 Mendelian disorders caused by private
founder mutations have been identified in Gypsy popu-
lation [4].
We analyzed the SLC12A3 gene in Gitelman syndrome
patients from unrelated Gypsy families living in different
European regions. In this article, we report a formerly
undescribed novel mutation present in all patients. This
is the largest series published to date of patients having
the same underlying mutation in this disease.
METHODS
Patients
A total of 20 patients with Gitelman syndrome from
12 European families were studied. Six families lived in
different regions of Spain, four out of these six families
living in Asturias (families I to IV), one in Leo´n (family
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Table 1. Clinical and biochemical characteristics of patients at diagnosis
Age Sex Height PMg PK PHCO3 UCa/Cr UCl
Patient years (M/F) Presenting manifestations (SDS) mg/dL FEMg % mEq/L FEK % mEq/L mg/mg mEq/L
I 9 M Syncope −1.50 1.44 12.9 2.6 18.7 29.1 0.01 139
II.1 12 F Familial study +0.62 1.19 9.1 3.4 15.3 33.0 0.01 124
II.2 8 F Cramps +0.29 1.24 9.5 3.2 16.9 25.8 0.02 97
II.3 19 F Familial study −0.33 1.27 9.2 3.0 18.3 28.5 0.03 181
III.1 8 F Hypokalemia −1.50 1.55 10.0 3.3 17.9 24.2 0.03 105
III.2 4 M Familial study +1.42 1.55 15.8 3.6 – 24.1 0.01 84
IV 12 M Vomiting and growth failure −2.82 1.17 12.7 2.8 31.0 31.7 0.01 117
V 5 F Hypokalemia −1.17 1.38 16.7 3.0 29.5 28.1 0.01 101
VI.1 9 F Cramps −1.92 1.17 10.9 2.9 26.0 28.0 0.02 167
VI.2 5 F Familial study −1.12 1.40 9.1 2.9 14.6 26.5 0.02 179
VII 6 M Hypokalemia −0.16 1.46 5.3 3.1 33.0 28.3 0.02 150
VIII 16 F Hypokalemia +0.87 1.29 – 2.7 19.6 28.0 0.03 –
IX 10 F Fatigue +0.32 1.20 5.4 2.2 19.2 30.6 0.01 85
X.1 1 F Vomiting −2.04 1.50 3.6 2.4 30.2 24.5 0.01 101
X.2 5 F Growth failure −3.35 1.40 4.6 2.8 14.6 31.5 0.01 98
XI.1 13 F Hypokalemia −0.75 1.10 3.6 2.7 21.0 33.0 0.01 107
XI.2 10 F Familial study −0.78 1.30 3.8 2.8 15.9 27.3 0.01 141
XI.3 3 M Familial study −1.77 1.40 4.0 2.9 26.0 31.5 0.01 179
XII.1 9 F Acute abdomen: pseudo-occlusion −2.60 1.12 6.7 2.3 16.2 29.0 0.02 95
XII.2 7 F Abdominal cramps −1.93 1.25 12.4 2.9 21.7 28.0 0.02 101
Abbreviations are: M, male; F, female; SDS, standard deviation score in comparison with age- and sex-matched reference population; P, plasma; FE, fractional
excretion; U, urinary; Ca/Cr, calcium/creatinine ratio.
V), and other one in Zaragoza (family VI). Three fam-
ilies lived in Germany (families VII, VIII, and IX), two
families lived in Portugal (families X and XI), and an-
other one in France (family XII). The patients and their
families were of Gypsy race and did not recognize any
kind of relativeness. Informed consent was obtained from
each participating subject or the parents of the younger
children.
Diagnosis of Gitelman syndrome was based on the
association of hypomagnesemia (<1.6 mg/dL) and hy-
pokalemia (<3.5 mEq/L) with inappropriately high
urinary excretions of magnesium and potassium and
hypocalciuria [5]. Patients had normal blood pressure and
their urinary chloride was in excess of 10 mEq/L in the
presence of metabolic alkalosis. No patient was taking
any medication, particularly diuretics. Clinical and bio-
chemical findings of patients at the time of diagnosis are
summarized in Table 1.
Sequencing and genotyping
Genomic DNA of patients was amplified in a final
volume of 30 lL with 26 primer pairs that flanked the
26 exons of the SLC12A3 gene. These primers matched
the intronic sequencies and had been previously de-
scribed [2, 6]. The 26 polymerase chain reaction (PCR)
products from each patient were purified from agarose
gels (DNA gel extraction kit, Millipore, Bedford, MA,
USA) and sequenced in an automated system (ABI
610) using dRhodamine terminator Cycle sequencing
(Perkin Elmer, Warrington, UK) and the primers used for
amplifications.
DNA samples from the patients, their relatives, as well
as from 200 healthy Spanish control patients were ana-
lyzed. Genomic DNA was PCR-amplified with primers
9F = CTCTCTCCCTCCCTCCTTCAG and 9R = CTG
GCTGGGCCGGCCAGTT (annealing at 68◦C). The re-
verse primer contains a mismatch that introduces a site
for the restriction enzyme HpaI when T is present. Af-
ter digestion with this enzyme, the amplification products
were subjected to electrophoresis on a 3% agarose gel
and stained with ethidium bromide.
RESULTS
Clinical and biochemical data
As shown in Table 1, six patients were diagnosed with
Gitelman syndrome as a result of familial studies carried
out after one sibling had been identified as having the
disease. Those patients were free of symptoms, or at least
their potential manifestations had been so mild that hy-
pomagnesemia or hypokalemia had not formerly been
identified. Patients III.1, V, VII, VIII, and XI.1 were di-
agnosed because hypokalemia was noted in a diagnos-
tic work-up performed for reasons not apparently re-
lated with potassium or magnesium deficiency. Patients
IV, X.1, X.2, and XII.1 were markedly growth retarded,
their height being below –2SDS.
Genotyping and sequencing
We sequenced the 26 SLC12A3 exons in patients from
the 12 families. The only difference compared with the
normal sequence was a G>T in the first position of in-
tron 9 (Fig. 1). Because this nucleotide change affects the
consensus donor splice site motif, it likely abolishes cor-
rect RNA splicing and gives rise to a nonsense protein. All
Coto et al: Intron 9 + 1 G>T is linked to Gitelman syndrome in Gypsies 27
A
B
Fig. 1. Representative DNA sequence analysis in (A) a patient and
one of the (B) healthy control patients. The analysis reveals a novel
homozygous mutation, guanine to thymine.
index patients, as well as their apparently asymptomatic
siblings, were homozygous for this mutation, whereas
their parents were proved to carry only one mutant al-
lele. Restriction fragment length polymorphism analysis
of the PCR-amplified DNA fragments demonstrated ab-
sence of the mutation in 200 control individuals. The nor-
mal allele was visualized as one single fragment of 151
bp, and the T mutation allele as two bands of 131+20 bp
(Fig. 2).
DISCUSSION
Gitelman syndrome is linked to mutations in the
SLC12A3 gene, which encodes the thiazide-sensitive
sodium-chloride cotransporter. Patients with classic Bart-
ter syndrome carry inactivating mutations of the CLC-
NKB gene, which encodes the chloride channel ClC-Kb.
Both tubular disorders are characterized by hypokalemic
alkalosis, but whereas patients with Gitelman syndrome
are hypocalciuric and typically present in childhood or
adolescence with mild symptoms, patients with Bart-
ter syndrome are normocalciuric or hypercalciuric and
present earlier, frequently with failure-to-thrive in early
infancy. However, there is increasing evidence for a phe-
notypic overlap between both disorders [7, 8]. Jeck et al
[9] reported mutations in the CLCNKB gene in three
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Fig. 2. Restriction-fragment-length polymorphism analysis of poly-
merase chain reaction–amplified fragment in exon 9 of SLC12A3 gene.
After digestion with HpaI, the normal G-allele is seen as a 151 bp band
whereas the fragment holding the mutation (T) is detected as a 131 bp
band. Lanes 1 and 2 correspond to patients. Lanes 3, 4, and 8 correspond
to healthy control patients. Lanes 5, 6, and 7 correspond to heterozygous
parents.
unrelated patients with a clinically mixed form of Bartter
syndrome and Gitelman syndrome. Recently, Zelikovic
et al [8] have also reported a Bedouin kindred with a
hereditary hypokalemic tubulopathy in which the bio-
chemical and clinical evaluation of the 12 affected mem-
bers revealed phenotypic features of both Gitelman and
Bartter syndromes. These patients were found to carry
the same homozygous missense mutation in the CLC-
NKB gene. Linkage analysis excluded involvement of the
SLC12A3 gene. NCCT is situated along the luminal side
of DCT cells, ensuing sodium chloride entry from the
tubular lumen into the cell. ClC-Kb is situated at the ba-
solateral side of the DCT cells and mediates chloride exit
from the cell into the blood [10, 11]. Thus, inactivating mu-
tations of CLCNKB or SLC12A3 genes will cause a dys-
function in the same pathway for transepithelial chloride
reabsorption at the DCT [12] and may give rise to phe-
notypic manifestations overlapping classic Bartter syn-
drome and Gitelman syndrome. By contrast, inactivating
mutations in the genes encoding the furosemide-sensitive
sodium-chloride cotransporter NKCC2, the renal potas-
sium channel, ROMK, or the Barttin protein, a ClC-K
chloride channel subunit, proteins predominantly located
in the thick ascending limb of Henle’s loop will lead to
a phenotype mimicking chronic furosemide administra-
tion. These patients are born preterm due to maternal
polyhydramnios. Postnatally, they exhibit hypokalemic
alkalosis, polyuria, hypercalciuria with nephrocalcinosis,
dehydration, and failure-to-thrive characteristic of in-
fants with hyperprostaglandin E syndrome/antenatal
Bartter syndrome [13].
More than 100 different mutations in the SLC12A3
gene have been described in patients with Gitelman syn-
drome [14]. Most of the reported mutations are single-
nucleotide changes distributed through the 26 exons,
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which change the amino acid (missense) or insert a
stop codon (nonsense). All the intron boundaries of the
SLC12A3 gene have the conventional 5′GT-3′AG con-
sensus splice sites. Mutations in these nucleotides would
affect the correct mRNA splicing [15]. A few splicing mu-
tations have been identified in patients with Gitelman
syndrome. Our Gypsy patients were homozygous for the
same splice site mutation (intron 9 +1 G>T). This is a
novel mutation formerly undescribed in individuals with
Gitelman syndrome. The parents of our patients were
heterozygotes for the mutation. Although a single mu-
tant allele has been found in approximately 40% of pa-
tients with Gitelman syndrome [2, 3, 6], the parents of our
children did not have hypokalemia or hypomagnesemia,
indicating that they were asymptomatic carriers of the
mutation.
To the best of our knowledge, 10 Mendelian disor-
ders have been shown to be caused by private founder
mutations in the Roma. The list includes three specific
neurologic disorders—hereditary motor and sensory
neuropathies type Lom and type Russe, congenital
cataracts facial dysmorphism neuropathy syndrome—
and other rare disorders such as primary congenital glau-
coma, galactokinase deficiency, polycystic kidney dis-
ease, limb girdle muscular dystrophy type 2C, congenital
myasthenia, Glanzmann trombasthenia, and type 3 von
Willebrand disease [4]. In Gypsy population, Mendelian
disorders have usually been described as genetically
homogeneous, with a single mutation accounting for
all affected individuals and related polymorphic haplo-
types unambiguously pointing out to a common origin
and founder effect. Therefore, our findings suggest that
the mutation found in our patients is characteristic of
Gitelman syndrome in the Roma population. The iden-
tical mutation detected in Gypsy families from different
geographic regions suggests an ancient mutation origi-
nating from a common ancestor. Our results are of in-
terest not only to gain understanding on the genetic
basis of this disease but also to facilitate its diagno-
sis. Given the wide array of mutations described in the
SLC12A3 gene, a gene of large size, the search of the
underlying mutation in a new patient with Gitelman
syndrome is frequently time-consuming and labor-
demanding. On the basis of our results, the investigation
of the SLC12A3 gene in a Gypsy patient with typical
laboratory features of Gitelman syndrome should be ini-
tially confined to the analysis of the mutation reported
here.
It is also of note that our group of 20 patients accounts
for the largest series ever reported of Gitelman syndrome
patients from different families sharing the same muta-
tion. This confirms the different phenotype of the dis-
ease in unrelated affected individuals with a common
genetic defect. Several of our patients were diagnosed
as a result of a familial study and denied having symp-
toms even when they were specifically asked about usual
manifestations of the syndrome. In this regard, Cruz et al
[16] have recently reported that none of 50 adult pa-
tients with Gitelman syndrome were truly asymptomatic
when interviewed by a questionnaire. Thus, it may be
assumed that our currently asymptomatic children will
develop symptoms related with the potassium and/or
magnesium depletion in the future. Manifestations such
as cramps, syncope, or marked growth failure were
present in other individuals. Salt craving, musculoskele-
tal symptoms, generalized weakness, and dizziness have
been reported to be the most prevalent symptoms of
Gitelman syndrome [16]. Although growth retardation
is characteristic of Bartter syndrome, it has also been
found in children with Gitelman syndrome [17–19], in
some sporadic cases in association with growth hormone
deficiency [20, 21]. Our study provides evidence of the
clinical heterogeneity of the disease even in the pres-
ence of a common underlying mutation. It is of note
that, as shown in Table 1, the biochemical alterations
found in the patients were quite uniform, regardless
of the clinical manifestations of the disease, which var-
ied from lack of symptoms to marked growth failure.
Thus, the clinical heterogeneity cannot be explained by
a different severity of the electrolytic disorder at the
time of diagnosis. On the other hand, no other potential
causes of growth retardation, such as nutritional deficits
or associated genetic diseases, were identified in our
patients.
CONCLUSION
This study demonstrates a new mutation in GYPSY
patients with Gitelman syndrome and supports the lack
of correlation between genotype and phenotype in this
disease.
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